This segment focuses on the research, development, and commercialization of innovative therapies for various cancers. Research and development activities include the discovery and preclinical development of novel drug candidates, followed by clinical trials to evaluate safety and efficacy. Technologies employed include small molecule inhibitors, such as Orelabrutinib (ICP-022), a Bruton's tyrosine kinase inhibitor for treating hematological malignancies, and Gunagratinib (ICP-192), a pan-FGFR inhibitor. The segment addresses significant unmet needs in oncology, aiming to improve patient outcomes and survival rates. Market positioning involves competing with established pharmaceutical companies and emerging biotech firms. Future opportunities include expanding the pipeline with new drug candidates and geographic expansion. Regulatory and clinical aspects involve navigating complex approval processes and conducting clinical trials across multiple phases. Partnerships and collaborations are essential for accessing resources, expertise, and markets, as seen with Biogen's terminated collaboration on Orelabrutinib.

This segment is dedicated to the development of treatments for autoimmune diseases. Research and development efforts focus on identifying and validating drug targets, designing and synthesizing drug candidates, and conducting preclinical and clinical studies. The segment utilizes various technologies, including small molecule inhibitors, such as ICP-332, a small-molecule inhibitor of tyrosine kinase 2 (TYK2) for the treatment of various T-cell mediated autoimmune disorders. The therapeutic areas covered include psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The patient impact is significant, as these therapies aim to alleviate symptoms, slow disease progression, and improve the quality of life for patients. Market positioning involves competing with existing therapies and emerging treatments. Future opportunities include expanding the pipeline with new drug candidates and exploring new indications. Regulatory and clinical aspects involve obtaining regulatory approvals and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are essential for accessing resources, expertise, and markets.